Literature DB >> 15615261

Decrease of CD4+ and B-lymphocyte populations is not associated with severe infectious complications in children with acute lymphoblastic leukemia during maintenance.

Stavroula Kostaridou1, Sophia Polychronopoulou, Katherine Psarra, Violetta Kapsimali, Agapi Parcharidou, Prokopis Katevas, Chrysa Papasteriades, Stavros Haidas.   

Abstract

The suppression of lymphopoiesis and immune competence during the maintenance phase in children with acute lymphoblastic leukemia (ALL) and the occurrence of infectious complications remain an unexplored area. In this study we assessed lymphocyte subpopulation disturbances during maintenance for childhood ALL along with the incidence, type, and severity of infections that occur during that period in the absence of neutropenia. Twenty-eight children (13 boys, 15 girls) with ALL aged 3-14 years (median 7 years) and treated according to the ALL-BFM 90/95 protocol were studied during maintenance for ALL. Complete white blood cell (WBC) counts and peripheral blood lymphocyte (PBL) analyses were performed. Major lymphocyte subsets (CD19+, CD3+CD4+, CD3-CD8+, CD3-CD16+CD56+, CD45RA-, CD45RO+) and markers of T-cell activation (CD25, CD38, CD69, HLA-DR) were analyzed with flow cytometry. Serum immunoglobulin G (IgG), IgA, and IgM levels were measured by a nephelometric assay. All infectious episodes during the study period were recorded in detail. Additionally, 41 age-matched immunocompetent children were used as controls. Absolute WBC counts (median, 3627/microL) and PBL counts (median, 1206/microL) were significantly below the age-adjusted control values (7400/microL and 2673/microL, respectively; P < .0001). B-lymphocyte, total CD4+, and memory CD4+ (CD4+CD45RO+) subsets were also significantly decreased (33/microL versus 377/microL [P < .0001], 531/microL versus 1045/microL [P < .01], and 80/microL versus 299/microL [P < .001], respectively). Significantly lower immunoglobulin levels were found in all patients. Twenty-two of the 28 patients presented with 74 episodes of a variety o minor infections (mostly respiratory viral [39], skin [7], and gastrointestinal [3]), none demanding prolonged hospital treat ment. Our findings demonstrate a profound immunosuppression throughout maintenance therapy in children with ALL tha has no major clinical impact in terms of increased incidence or severity of systemic infections.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15615261     DOI: 10.1532/ijh97.e0317

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  23 in total

1.  Recovery of blood B-lymphocytes and serum immunoglobulins after chemotherapy for childhood acute lymphoblastic leukemia.

Authors:  S Alanko; T T Pelliniemi; T T Salmi
Journal:  Cancer       Date:  1992-03-15       Impact factor: 6.860

Review 2.  The child with cancer and infection. I. Empiric therapy for fever and neutropenia, and preventive strategies.

Authors:  P A Pizzo; M Rubin; A Freifeld; T J Walsh
Journal:  J Pediatr       Date:  1991-11       Impact factor: 4.406

3.  The differential effect of in vivo hydrocortisone on the kinetics of subpopulations of human peripheral blood thymus-derived lymphocytes.

Authors:  B F Haynes; A S Fauci
Journal:  J Clin Invest       Date:  1978-03       Impact factor: 14.808

4.  Prolonged defects of interleukin-2 production, responsiveness, and receptor expression in patients with acute lymphoblastic leukemia.

Authors:  M S Borzy; D Ridgway
Journal:  Blood       Date:  1989-05-01       Impact factor: 22.113

5.  Infectious complications in children with acute lymphoblastic leukemia and T-cell lymphoma--a rationale for tailored supportive care.

Authors:  C Lex; D Körholz; B Kohlmüller; H Bönig; R Willers; C M Kramm; U Göbel
Journal:  Support Care Cancer       Date:  2001-10       Impact factor: 3.603

6.  Immune response of immunocompromised children with malignancies to a recombinant hepatitis B vaccine.

Authors:  S Polychronopoulou-Androulakaki; J P Panagiotou; S Kostaridou; A Kyratzopoulou; S Haidas
Journal:  Pediatr Hematol Oncol       Date:  1996 Sep-Oct       Impact factor: 1.969

7.  Long-term abnormalities in T and B lymphocyte function in children following treatment for acute lymphoblastic leukaemia.

Authors:  L Layward; R J Levinsky; M Butler
Journal:  Br J Haematol       Date:  1981-10       Impact factor: 6.998

8.  Age-related changes in human blood lymphocyte subpopulations.

Authors:  F M Erkeller-Yuksel; V Deneys; B Yuksel; I Hannet; F Hulstaert; C Hamilton; H Mackinnon; L T Stokes; V Munhyeshuli; F Vanlangendonck
Journal:  J Pediatr       Date:  1992-02       Impact factor: 4.406

9.  Cellular immunosuppression in children with acute lymphoblastic leukemia: effect of consolidation chemotherapy.

Authors:  Y Komada; S L Zhang; Y W Zhou; M Hanada; T Shibata; E Azuma; M Sakurai
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

10.  Immunodeficiency in long-term survivors of acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster therapy.

Authors:  S Smith; G Schiffman; G Karayalcin; V Bonagura
Journal:  J Pediatr       Date:  1995-07       Impact factor: 4.406

View more
  3 in total

1.  Prevalence and Safety of Intravenous Immunoglobulin Administration During Maintenance Chemotherapy in Children with Acute Lymphoblastic Leukemia in First Complete Remission: A Health Maintenance Organization Perspective.

Authors:  Patrick Van Winkle; Raoul Burchette; Raymond Kim; Rukmani Raghunathan; Naveen Qureshi
Journal:  Perm J       Date:  2018

2.  Infections in a pediatric patient cohort with acute lymphoblastic leukemia during the entire course of treatment.

Authors:  Katerina Katsimpardi; Vassilios Papadakis; Anastasia Pangalis; Agapi Parcharidou; John P Panagiotou; Michael Soutis; Evangelos Papandreou; Sophia Polychronopoulou; Stavros Haidas
Journal:  Support Care Cancer       Date:  2005-11-04       Impact factor: 3.603

3.  Hypogammaglobulinemia in Adolescents and Young Adults with Acute Lymphoblastic Leukemia.

Authors:  Cassandra S Lange; April Rahrig; Sandra K Althouse; Robert P Nelson; Sandeep Batra
Journal:  J Adolesc Young Adult Oncol       Date:  2020-07-13       Impact factor: 1.757

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.